SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Research and Markets: HIV/AIDS Therapeutics Market to 2018
[November 23, 2012]

Research and Markets: HIV/AIDS Therapeutics Market to 2018


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/cnk25v/hivaids) has announced the addition of the "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth" report to their offering.

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire

Gilead Science's combination drug Stribild (previously known as the Quad pill) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.

Forecasts from the firm's latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billon.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.


Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, GBI Research do not expect this higher cost to be a significant barrier to widespread use.

Last year's sales figures show Gilead as being the greatest revenue shareholder of the world's top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Companies Mentioned

- Gilead Sciences, Inc

- GlaxoSmithKline (GSK)

- BMS

- Abbott Laboratories

- Merck

- Johnson & Johnson (J&J)

- Roche

For more information visit http://www.researchandmarkets.com/research/cnk25v/hivaids.


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy